Cleerly ISCHEMIA vs Viz RV/LV

Viz RV/LV offers superior usability through its emphasis on intelligent care coordination, AI-powered alerts, and a high-fidelity mobile DICOM image viewer, facilitating rapid decision-making and communication in acute settings. While Cleerly ISCHEMIA provides comprehensive web-based reports and API integration for detailed analysis, Viz RV/LV's features are more geared towards immediate, actionable insights and collaborative workflows for a broader care team.

Cleerly ISCHEMIA provides a deeper and more comprehensive diagnostic assessment of coronary artery disease, including non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization. This offers crucial physiological insights for personalized long-term treatment planning, potentially reducing the need for additional invasive testing. While Viz RV/LV is critical for rapid pulmonary embolism risk stratification, Cleerly's broader and more in-depth assessment for chronic disease management offers a higher overall clinical value for guiding personalized treatment strategies.

While both tools lack fully transparent public pricing, Cleerly ISCHEMIA provides more tangible pricing information, with some sources indicating a retail price per analysis (around $1500) and billability under a Category I CPT code. This offers a clearer path for reimbursement and cost-benefit analysis for providers. Viz RV/LV operates on a subscription model with less public detail, making it harder to assess direct value without institutional negotiation.

Viz RV/LV demonstrates stronger enterprise readiness through its proven scalability, deployed at 2,000 hospitals and covering two-thirds of the U.S. population, and its emphasis on intelligent care coordination with AI-powered alerts and a HIPAA-compliant communication platform. Its integration within the broader Viz PE Solution and partnerships to facilitate AI adoption suggest a more mature and comprehensive enterprise-level deployment and support strategy. Cleerly ISCHEMIA, while HIPAA compliant and BAA-ready, does not provide as much evidence of widespread enterprise integration and care coordination features.

Cleerly ISCHEMIA exhibits greater innovation in its diagnostic depth by providing non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans. This moves beyond traditional anatomical assessment to offer physiological insights, potentially transforming personalized diagnosis and treatment planning for heart disease. While Viz RV/LV innovates in acute care coordination and rapid alerts, Cleerly's advancement in non-invasive physiological assessment represents a more profound diagnostic innovation.

Viz RV/LV clearly wins in this dimension, as Viz.ai explicitly highlights a dedicated customer success team, clinical and workflow specialists, and a comprehensive support center with multiple contact options. This level of structured support and resources is crucial for successful implementation and ongoing optimization in a clinical setting. Cleerly ISCHEMIA's information does not detail comparable support and documentation offerings.